{"summary":"Specialist medical oncologist and associate professor of oncology at Karolinska Institutet, with a clinical and research interest in breast cancer. Received a MD from Aristotle University Medical School, Greece with a scholarship for academic excellence, a MSc in cancer cell biology from Athens Medical School as the valedictorian and a Doctoral Degree (PhD) in circulating tumor cells from Crete Medical School. Following a 1-year research fellowship under the ESMO Georges Math\u00e9 fellowship for immuno-oncology (2016-2017, Karolinska Institutet), 11\/2017 I started working as postdoc on breast cancer immunology at Karolinska Institutet and as a consultant physician at the breast cancer center, Karolinska University Hospital. Appointed as senior consultant physician on 2\/2021 and associate professor of oncology on 5\/2021. Member of the Leadership Development committee, the OncologyPRO working group and the Magnitude of Clinical Benefit Scale working group of the European Society for Medical Oncology. Recipient of the Junior Clinical Investigator award 2021 from the Swedish Cancer Society (Cancerfonden).","lastName":"Matikas","objectUrn":"urn:li:member:284857497","geoRegion":"Stockholm County, Sweden","fullName":"Alexios Matikas","firstName":"Alexios","currentPositions":[{"companyName":"Karolinska Institutet","title":"Assistant director of doctoral studies (bitr\u00e4dande studierektor f\u00f6r forskarutbildning), OnkPat","tenureAtCompany":{"numMonths":1},"companyUrnResolutionResult":{"employeeCountRange":"1001-5000","headquarters":{"country":"Sweden","city":"Solna","line1":"Nobels v\u00e4g 6, Solna"},"website":"http:\/\/ki.se","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/karolinska-institutet\/","industry":"Higher Education"},"startedOn":{"month":5,"year":2024},"companyUrn":"urn:li:fs_salesCompany:5366"}],"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1516789718758?e=1723075200&v=beta&t=ftS8KgxNAoGyDHNf0kr14myQbD34S0xP4_5XUAA91Xc","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1516789718671?e=1723075200&v=beta&t=WVV82FLujoygjEpcg-qbMIVp39_y34ej4dG_-uQofXE","height":200},{"width":326,"fileIdentifyingUrlPathSegment":"400_400\/0\/1516789718550?e=1723075200&v=beta&t=GPEiuJLd59Etr5TbeRtQ5_hrMTiGFMJyqkxeFYcozHA","height":326},{"width":326,"fileIdentifyingUrlPathSegment":"800_800\/0\/1516789718688?e=1723075200&v=beta&t=t7zsT04GwKmX0RS26McAJswxLHTm9wEmDnJeslCyUF8","height":326}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/C4E03AQFbxSRcmhWzBQ\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Hospitals and Health Care","educations":[{"school":"urn:li:fs_salesSchool:5366","degree":"Postdoctoral Researcher","schoolName":"Karolinska Institutet","schoolUrn":"urn:li:fs_salesSchool:5366","eduId":473697497},{"degree":"Medical Oncology Specialty","schoolName":"University Hospital of Heraklion","eduId":320438754},{"endedOn":{"year":2017},"degree":"Doctor of Philosophy (Ph.D.)","eduId":228657534,"fieldsOfStudy":["Micrometastatic disease in colorectal cancer"],"schoolName":"University of Crete Medical School","startedOn":{"year":2014}},{"endedOn":{"year":2012},"degree":"Master's degree","eduId":228657460,"schoolUrn":"urn:li:fs_salesSchool:15094179","school":"urn:li:fs_salesSchool:15094179","fieldsOfStudy":["Oncology and Cancer Biology"],"schoolName":"Ethnikon kai Kapodistriakon Panepistimion Athinon","startedOn":{"year":2010}},{"endedOn":{"year":2006},"degree":"Doctor of Medicine (M.D.)","eduId":228654752,"schoolUrn":"urn:li:fs_salesSchool:15094947","school":"urn:li:fs_salesSchool:15094947","schoolName":"Aristoteleion Panepistimion Thessalonikis","startedOn":{"year":2000}}],"skills":[{"numOfEndorsement":5,"name":"Hospitals"},{"numOfEndorsement":12,"name":"Clinical Research"},{"numOfEndorsement":11,"name":"Medicine"},{"numOfEndorsement":10,"name":"Internal Medicine"},{"numOfEndorsement":13,"name":"Oncology"},{"numOfEndorsement":5,"name":"Clinical Trials"},{"numOfEndorsement":2,"name":"ACLS"},{"numOfEndorsement":0,"name":"Chemotherapy"},{"numOfEndorsement":0,"name":"Cancer Biology"},{"numOfEndorsement":0,"name":"Hospital Medicine"},{"numOfEndorsement":1,"name":"Medical Education"},{"numOfEndorsement":4,"name":"Healthcare"},{"numOfEndorsement":9,"name":"Cancer"},{"numOfEndorsement":6,"name":"Cancer Research"},{"numOfEndorsement":4,"name":"Epidemiology"},{"numOfEndorsement":6,"name":"Medical Research"},{"numOfEndorsement":2,"name":"Board Certified"},{"numOfEndorsement":3,"name":"Life Sciences"},{"numOfEndorsement":3,"name":"Hematology"}],"numOfConnections":556,"patents":[],"headline":"Associate Professor of Oncology at Karolinska Institutet","courses":[],"certifications":[{"endedOn":{"month":6,"year":2025},"companyUrn":"urn:li:fs_salesCompany:481100","authority":"European Society for Medical Oncology - ESMO","name":"ESMO Examination Certification","company":"urn:li:fs_salesCompany:481100","startedOn":{"month":9,"year":2015}},{"authority":"Royal College of Physicians of the United Kingdom","name":"Specialist Certification in Medical Oncology","company":"urn:li:fs_salesCompany:36567","startedOn":{"month":9,"year":2015},"companyUrn":"urn:li:fs_salesCompany:36567"}],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/alexios-matikas-1094947b","organizations":[{"name":"American Society of Clinical Oncology","position":"Member in training","startedOn":{"year":2015}},{"name":"European Society for Medical Oncology","position":"Junior member","startedOn":{"month":4,"year":2015}},{"name":"Hellenic Society of Medical Oncology","position":"Young Oncologists Group","startedOn":{"year":2012}}],"location":"Stockholm County, Sweden","publications":[{"name":"Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges","publishedOn":{"month":6,"day":8,"year":2016},"publisher":"Clinical Lung Cancer","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27373516","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer","publishedOn":{"month":6,"day":2,"year":2016},"publisher":"Clinical Lung Cancer","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27341790","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAjDv54B9iThWpEs5EFFebrSWMLnO4evAiw,NAME_SEARCH,oYXB)"}]},{"name":"Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).","publishedOn":{"month":6,"day":22,"year":2016},"publisher":"Cancer Chemotherapy and Pharmacology","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27335027","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAxdp3kBfhYLQQDgTk48fcqOT_bNFqDlCvM,NAME_SEARCH,LvCg)"}]},{"name":"Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients","publishedOn":{"month":5,"year":2016},"publisher":"Expert Opinion on Emerging Drugs","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27139914","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAjDv54B9iThWpEs5EFFebrSWMLnO4evAiw,NAME_SEARCH,oYXB)"}]},{"name":"Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients","publishedOn":{"month":8,"year":2015},"publisher":"Breast Cancer Research","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26285572","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAemO-4B2gqrBPp5IE2Ocbx3GjUtjFDBpwM,NAME_SEARCH,ynJD)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAjDv54B9iThWpEs5EFFebrSWMLnO4evAiw,NAME_SEARCH,oYXB)"}]},{"name":"Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer","publishedOn":{"month":5,"year":2015},"publisher":"BMC Cancer","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25962645","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAjDv54B9iThWpEs5EFFebrSWMLnO4evAiw,NAME_SEARCH,oYXB)"}]},{"name":"Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs","publishedOn":{"month":7,"year":2015},"publisher":"Clinical Lung Cancer","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25700775","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAjDv54B9iThWpEs5EFFebrSWMLnO4evAiw,NAME_SEARCH,oYXB)"}]},{"name":"Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma","publishedOn":{"month":3,"year":2015},"publisher":"Future Oncology","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25760979","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Triple-negative breast cancer: one or more entities?","publishedOn":{"month":12,"year":2014},"publisher":"Forum of Clinical Oncology","url":"http:\/\/www.degruyter.com\/view\/j\/fco.2014.5.issue-2\/fco-2014-0010\/fco-2014-0010.xml?format=INT","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Pre-Column Derivatization HPLC Procedure for the Quantitation of Aluminium Chlorohydrate in Antiperspirant Creams Using Quercetin as Chromogenic Reagent","publishedOn":{"month":9,"year":2014},"publisher":"Chromatographia","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25278619","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAUeHcUB--gh4YYM_70VGLd1rW7BOhmoQ0o,NAME_SEARCH,J3Fs)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAGh51IBnceX4HlZmwAfqRuyXRH2EgVRQv0,NAME_SEARCH,h0eW)"}]},{"name":"Plasmablastic lymphoma of the breast in an immunocompetent patient: long-lasting complete response induced by chemotherapy and autologous stem cell trasplantation","publishedOn":{"month":9,"year":2014},"publisher":"Anticancer Research","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25202100","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAjDv54B9iThWpEs5EFFebrSWMLnO4evAiw,NAME_SEARCH,oYXB)"}]},{"name":"A case of herpes simplex-associated encephalitis after brain irradiation for lung cancer metastases","publishedOn":{"month":8,"year":2014},"publisher":"Anticancer Research","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25075078","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer: a multicenter phase II study of the Hellenic Oncology Research Group","publishedOn":{"month":4,"year":2014},"publisher":"BMC Cancer","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24755296","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAjDv54B9iThWpEs5EFFebrSWMLnO4evAiw,NAME_SEARCH,oYXB)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAFckLsBbqpYVpN5v7Q8i0QArhtjPzWx4MQ,NAME_SEARCH,Kero)"}]},{"name":"A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation","publishedOn":{"month":9,"year":2013},"publisher":"BMJ Case Reports","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24045761","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAArkIiwBbe2Klf0W44iOEWRqCOBaPl3-u2g,NAME_SEARCH,F7Kq)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAFckLsBbqpYVpN5v7Q8i0QArhtjPzWx4MQ,NAME_SEARCH,Kero)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAjDv54B9iThWpEs5EFFebrSWMLnO4evAiw,NAME_SEARCH,oYXB)"}]},{"name":"Primary bone lymphoma: a retrospective analysis of 22 patients treated in a single tertiary center","publishedOn":{"month":11,"year":2013},"publisher":"Acta Haematologica","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24008727","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"A case of acute myelogenous leukaemia characterised by the BCR-FGFR1 translocation","publishedOn":{"month":3,"year":2013},"publisher":"BMJ Case Reports","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23519513","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Primary abdominal muscle lymphoma","publishedOn":{"month":1,"year":2013},"publisher":"BMJ Case Reports","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23329723","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer","publishedOn":{"month":3,"day":13,"year":2015},"publisher":"Cancers(Basel)","url":"http:\/\/25782007","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA-WhF0BTC6PO6zfD0qyOt1ZYsZj7qfwGJs,NAME_SEARCH,stEU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAkXjtkBCLknrD7Mk-KtAOey98XIWfOV2VQ,NAME_SEARCH,D95V)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAFckLsBbqpYVpN5v7Q8i0QArhtjPzWx4MQ,NAME_SEARCH,Kero)"}]},{"name":"Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI","publishedOn":{"month":5,"day":21,"year":2015},"publisher":"Case Reports in Oncological Medicine","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26090249","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD69hYB6YZyVnSik4eUcXZcqd9sHsbbO4s,NAME_SEARCH,g6TC)"}]},{"name":"Expression of Insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes","publishedOn":{"month":8,"year":2017},"publisher":"Molecular Oncology","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28766847","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer","publishedOn":{"month":7,"year":2017},"publisher":"Translational Oncology","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28692881","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine","publishedOn":{"month":6,"year":2017},"publisher":"Critical Review in Oncology\/Hematology","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28477750","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer","publishedOn":{"month":5,"year":2017},"publisher":"Expert Reviews in Anticancer Therapy","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28128984","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity","publishedOn":{"month":2,"year":2017},"publisher":"Critical Reviews in Oncology\/Hemarology","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28109399","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts","publishedOn":{"month":9,"year":2017},"publisher":"Acta Oncologica","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28537808","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy","publishedOn":{"month":9,"year":2016},"publisher":"British Journal of Cancer","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27607471","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HOR","publishedOn":{"month":10,"year":2016},"publisher":"Annals of Oncology","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27502729","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer","publishedOn":{"month":4,"year":2018},"publisher":"Breast Cancer Research and Treatment","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29190004","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Immune gene expression and response to chemotherapy in advanced breast cancer","publishedOn":{"month":2,"year":2018},"publisher":"British Journal of Cancer","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29370583","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis","publishedOn":{"month":3,"year":2018},"publisher":"Journal of the National Cancer Institute","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29618043","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations","publishedOn":{"month":8,"year":2018},"publisher":"Oncogene","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29765155","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer.","publishedOn":{"month":7,"year":2018},"publisher":"Oncoimmunology","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30228933","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients","publishedOn":{"month":1,"year":2019},"publisher":"Annals of Oncology","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30357310","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Minimally invasive tissue access as a tool for delivering personalized medicine - with focus on oncology","publishedOn":{"month":4,"year":2019},"publisher":"Journal of Internal Medicine","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30488991","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"G-CSF-induced aortitis: Two cases and review of the literature","publishedOn":{"month":6,"year":2019},"publisher":"Autoimmunity Reviews","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30959218","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Beyond PD-1\/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy","publishedOn":{"month":5,"year":2019},"publisher":"Cancers","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31060337","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?","publishedOn":{"month":4,"year":2019},"publisher":"Annals of Oncology","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31131397","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?","publishedOn":{"month":7,"day":1,"year":2019},"publisher":"Annals of Oncology","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31131397","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data","publishedOn":{"month":9,"day":1,"year":2019},"publisher":"Clinical Cancer Research","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31227501","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer","publishedOn":{"month":10,"day":1,"year":2019},"publisher":"Acta Oncologica","url":"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31583943","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Efficacy and safety of adjuvant tailored dose dense chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial","publishedOn":{"month":10,"day":29,"year":2019},"publisher":"Cancer","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease","publishedOn":{"month":4,"day":29,"year":2020},"publisher":"Molecular Oncology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/32115850\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Chemotherapy use near the end-of-life in patients with metastatic breast cancer","publishedOn":{"month":6,"day":9,"year":2020},"publisher":"Breast Cancer Research and Treatment","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/32383058\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Efficacy and safety of cyclin dependent kinases 4\/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience","publishedOn":{"month":11,"day":9,"year":2020},"publisher":"Acta Oncologica","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/32783667\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"PD-1 protein and gene expression as prognostic factors in early breast cancer","publishedOn":{"month":11,"day":10,"year":2020},"publisher":"ESMO Open","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/33172959\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"SOLAR1s: alpelisib returns to earth?","publishedOn":{"month":2,"day":8,"year":2021},"publisher":"Annals of Oncology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/33309744\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer","publishedOn":{"month":3,"day":13,"year":2021},"publisher":"ESMO Open","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/33714010\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis","publishedOn":{"month":9,"day":1,"year":2021},"publisher":"Cancer Treatment Reviews","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34237488\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer","publishedOn":{"month":9,"day":16,"year":2021},"publisher":"Cancers","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34572882\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study","publishedOn":{"month":11,"day":19,"year":2021},"publisher":"npj Breast Cancer","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34799582\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Expert Discussion: HER2-Positive Breast Cancer","publishedOn":{"month":8,"day":1,"year":2021},"publisher":"Breast Care","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34602950\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study","publishedOn":{"month":7,"day":1,"year":2022},"publisher":"Breast Cancer Research and Treatment","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35461374\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Adjuvant abemaciclib for high-risk breast cancer: the story continues","publishedOn":{"month":12,"day":1,"year":2021},"publisher":"Annals of Oncology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34815015\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer","publishedOn":{"month":6,"day":1,"year":2022},"publisher":"British Journal of Cancer","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35145253\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Response to A. Chauhan and A. Pal","publishedOn":{"month":6,"day":1,"year":2022},"publisher":"British Journal of Cancer","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35379931\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution","publishedOn":{"month":4,"day":14,"year":2022},"publisher":"Cancers","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35454904\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Real World Evaluation of the Prosigna\/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study","publishedOn":{"month":5,"day":25,"year":2022},"publisher":"Cancers","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35681597\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Survival outcomes, digital TILs and on-treatment PET\/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial","publishedOn":{"month":11,"day":30,"year":2022},"publisher":"Clinical Cancer Research","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36449695\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period","publishedOn":{"month":6,"day":1,"year":2022},"publisher":"Breast Care","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35949417\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis","publishedOn":{"month":11,"day":30,"year":2022},"publisher":"Frontiers in Oncology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36531050\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Career and Professional Development for Young Oncologists","publishedOn":{"month":3,"day":1,"year":2023},"publisher":"Oncology Research and Treatment","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36473447\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"The interplay between eosinophils and T cells in breast cancer immunotherapy","publishedOn":{"month":4,"day":1,"year":2023},"publisher":"Molecular Oncology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/36892326\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis","publishedOn":{"month":9,"day":1,"year":2023},"publisher":"European Journal of Cancer","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37142539\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Young oncologists' perspective on the role and future of the clinician-scientist in oncology","publishedOn":{"month":10,"day":1,"year":2023},"publisher":"ESMO Open","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37659290\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Impact of Primary Breast Surgery on Overall Survival of Patients With De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis","publishedOn":{"month":1,"day":1,"year":2024},"publisher":"The Oncologist","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37700450\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review","publishedOn":{"month":12,"day":1,"year":2023},"publisher":"Critical Reviews in Oncology and Hematology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37866413\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Breast cancer during pregnancy-The oncologist's point of view","publishedOn":{"month":4,"day":1,"year":2024},"publisher":"Acta Obstetricia et Gynecologica Scandinavica","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37983830\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study","publishedOn":{"month":2,"day":1,"year":2024},"publisher":"Breast Cancer Research and Treatment","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38057688\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study","publishedOn":{"month":1,"day":1,"year":2024},"publisher":"JAMA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38059899\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial","publishedOn":{"month":4,"day":1,"year":2024},"publisher":"Breast Cancer Research and Treatment","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38175448\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients","publishedOn":{"month":3,"day":7,"year":2024},"publisher":"Breast Cancer Research","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38454481\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]},{"name":"Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors","publishedOn":{"month":4,"day":21,"year":2024},"publisher":"European Journal of Cancer","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38520926\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABD6lJkBmDh_UJPDIBlygOMwmd6QT3TMRwo,NAME_SEARCH,dQ72)"}]}],"positions":null,"posts":[{"createdAt":1716455160000,"insightId":"6777b111-1958-4fe6-841f-c16bc1261c00","activityUnion":{"postActivity":{"contentSummaryUnion":{"referenceContentSummary":{"entityUrn":"urn:li:celebrateJobChange:7199334889588981761"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":87},{"type":"PRAISE","count":24}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7199334890608160768","threadUrn":"urn:li:ugcPost:7199334890608160768","reactionsCount":111,"commentsCount":19,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7199334890608160768","message":{"attributes":[{"start":153,"length":21,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:5366"}}}],"text":"I\u2019m happy to share that I\u2019m starting a new position as Assistant director of doctoral studies (bitr\u00e4dande studierektor f\u00f6r forskarutbildning), OnkPat at Karolinska Institutet!"},"entityUrn":"urn:li:ugcPost:7199334890608160768"}}},{"createdAt":1716212280000,"insightId":"a1ccc53a-55b1-4e7d-8cff-92958a484f76","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7198298537862795264,7198316046443827201)","threadUrn":"urn:li:activity:7198298537862795264","reactionsCount":1,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Stort grattis!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7198298537862795264"}}},{"createdAt":1714667760000,"insightId":"df79540a-5bc2-4836-bff7-569b4018185a","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"PRAISE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7191810463632912387,7191838027734773761)","threadUrn":"urn:li:ugcPost:7191810463632912387","reactionsCount":1,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Grattis!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7191810463632912387"}}},{"createdAt":1712067480000,"insightId":"c0657c99-62a9-42ee-b1fa-37a180eacd2e","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7180891927469322240,7180931521350955009)","threadUrn":"urn:li:ugcPost:7180891927469322240","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Stort grattis!!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7180891927469322240"}}},{"createdAt":1711104480000,"insightId":"af51957f-76a4-4374-aa25-02ffc07a7a1b","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"EMPATHY","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7176877404408188928,7176892370389528577)","threadUrn":"urn:li:activity:7176877404408188928","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Grattis!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7176877404408188928"}}}]}